ENSYSCE BIOSCIENCES
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the company is in the process of developing a new class of tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.
ENSYSCE BIOSCIENCES
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2008-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.ensysce.com
Total Employee:
11+
Status:
Active
Contact:
+1 858 263 4196
Email Addresses:
[email protected]
Total Funding:
101.29 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins
Similar Organizations
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-01-19 | Signature Therapeutics, Inc. | Signature Therapeutics, Inc. acquired by Ensysce Biosciences | N/A |
Investors List
The Global Emerging Markets Group
The Global Emerging Markets Group investment in Private Equity Round - Ensysce Biosciences
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - Ensysce Biosciences
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - Ensysce Biosciences
Texas Wide Open for Business
Texas Wide Open for Business investment in Venture Round - Ensysce Biosciences
Texas Wide Open for Business
Texas Wide Open for Business investment in Series A - Ensysce Biosciences
Key Employee Changes
Official Site Inspections
http://www.ensysce.com
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ensysce Biosciences"
Ensysce Biosciences, Inc. (ENSC)
Apr 23, 2025 Ensysce Biosciences, Inc. 7946 Ivanhoe Ave Suite 201 La Jolla, CA 92037 T: 858-263-4196 [email protected]. Investor Relations. MZ North America 5055 Avenida Encinas …See details»
Ensysce Biosciences, Inc. - Crunchbase Company Profile & Funding
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company uses a proprietary technology …See details»
Ensysce Biosciences - LinkedIn
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the …See details»
Ensysce Biosciences, Inc. (ENSC) - Yahoo Finance
See the company profile for Ensysce Biosciences, Inc. (ENSC) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Ensysce Biosciences - Overview, News & Similar companies
Apr 18, 2022 Who is Ensysce Biosciences. Founded in 2017, Ensysce Biosciences, La Jolla, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer …See details»
Ensysce Biosciences Inc Company Profile - Overview
Ensysce Biosciences Inc (Ensysce Biosciences) is a clinical stage pharmaceutical company that develops solutions for severe pain relief. Its pipeline products include PF614 which treats pain …See details»
Ensysce Biosciences, Inc. - Drug pipelines, Patents, Clinical
About Ensysce Biosciences Ensysce Biosciences is a clinical stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated …See details»
Ensysce Biosciences (ENSC) Company Profile & Description - Stock …
It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use …See details»
About Us - Ensysce Biosciences
Ensysce Biosciences is developing first-in-class and uniquely innovative solutions in oral drug delivery.. Our proprietary TAAP™ and MPAR® technologies improve the care and safety of …See details»
Case Study: Ensysce Biosciences - Quotient Sciences
A case study on how Quotient Sciences' integrated Translational Pharmaceutics platform helped Ensysce Biosciences achieve a successful modified release formulation in an ... traditional …See details»
Ensysce - 2025 Company Profile, Funding & Competitors - Tracxn
Apr 28, 2025 Ensysce is a public company based in Houston (United States), founded in 2008. It operates as a Provider of drug delivery problems with Single-Walled Carbon Nanotubes. …See details»
FAQs :: Ensysce Biosciences, Inc. (ENSC)
Who is Ensysce Biosciences, Inc.'s transfer agent? Continental Stock Transfer & Trust Company 1 State Street 30 th Floor New York, NY 10004-1561 T: 212-509-4000. Who is Ensysce …See details»
Our Team - Ensysce Biosciences
“We can’t stop severe and chronic pain, but the Ensysce team are committed to helping manage it safely, using advanced chemistry” Experienced in the design of pre-clinical programs focused …See details»
Ensysce Biosciences Reports First Quarter 2025 Financial Results
May 13, 2025 SAN DIEGO, CA / ACCESS Newswire / May 13, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company …See details»
Ensysce Biosciences - VentureRadar
Ensysce are on a mission to launch the first two new classes of Opioids in decades – which protect against abuse and overdose while providing powerful relief for severe and chronic …See details»
Ensysce Biosciences Bolsters Management Team with Regulatory …
May 12, 2025 SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company …See details»
Ensysce Biosciences Bolsters Management Team with Regulatory …
May 12, 2025 SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company …See details»
Ensysce Biosciences Bolsters Management Team with Regulatory …
May 12, 2025 Ensysce Biosciences Company Contact: Lynn Kirkpatrick, Ph.D. Chief Executive Officer (858) 263-4196. Ensysce Biosciences Investor Relations Contact: Shannon Devine MZ …See details»
Contact - Ensysce Biosciences
Biotech company committed to stemming the prescription drug abuse epidemic. Our proprietary prodrug technologies are designed to improve the care of patients with severe pain while …See details»
Ensysce Biosciences Bolsters Management Team with Regulatory …
May 12, 2025 Ensysce Biosciences Company Contact: Lynn Kirkpatrick, Ph.D. Chief Executive Officer (858) 263-4196. Ensysce Biosciences Investor Relations Contact: Shannon Devine MZ …See details»